The Asia-Pacific Journal of Ophthalmology

Asia-Pacific Journal of Ophthalmology:

Articles in Press Original Study - Clinical

Asia-Pacific Technology and Trend Survey 2016–2017

Chhablani, Jay; Shaikh, Adnan; Goud, Abhilash; Kawasaki, Ryo; Kwon, Oh W.; Chang, Andrew; Lam, Dennis; Das, Taraprasad



Author Information


From the *Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, L V Prasad Eye Institute, Hyderabad, India; †Department of Vision Informatics (Topcon), Osaka University Graduate School of Medicine, Osaka, Japan; ‡Retina Center, Nune Eye Hospital, Seoul, South Korea; §Sydney Retina Clinic, University of Sydney, Australia, and ¶Dennis Lam & Partners Eye Center, Central, Hong Kong.


Reprints: Taraprasad Das, MS, Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, L V Prasad Eye Institute, Hyderabad-34, India. E-mail: tpdbei@gmail.com.



Abstract


Purpose: To report the results of a survey conducted among retina specialists in the Asia-Pacific region on real-life practice patterns in the management of vitreoretinal diseases.


Design: Prospective study.


Methods: In 2016 and 2017, a link was sent to 1400 retinal specialists across the Asia-Pacific region by e-mail, which directed to a web-based questionnaire (Google forms or Survey Monkey) with secure confidential access. The study had institutional review board approval. Answers to some of the common questions were compared with the 2016 American Society of Retina Specialists domestic and global trends.


Results: The surveys of 2016 and 2017 received 539 (38.5%) and 200 (14.3%) responses, respectively, across the Asia-Pacific region. Of the respondents, 85% practiced combined medical and surgical retina. The survey indicated that ranibizumab was the drug of choice (41% of respondents) in the management of wet age-related macular degeneration. In the management of polypoidal choroidal vasculopathy, both combination of verteporfin photodynamic therapy (vPDT ) and anti–vascular endothelial growth factor (VEGF) (n = 59%) and intravitreal aflibercept monotherapy (n = 53%) were preferred. Anti-VEGF treatment remained the first choice for center-involving diabetic macular edema (DME) (n = 78%) and switch to dexamethasone implant in nonresponding DME was preferred after 2–3 anti-VEGF injections (n = 53%).


Conclusions: The survey revealed information that may be close to real-world practices and could be of help to understand the transformation of global trends and practices due to evolving evidence and technologies.




Full Text

View PDF Online

Download PDF

APJO Express
2019
2018
2017
E-Newsletter+
2018
2017
2016

More About APAO

  • http://www.apaophth.org/
  • http://2019.apaophth.org/
  • http://www.apaophth.org/apao-ldp/
  • http://www.apaophth.org/fellowship-program/
  • 1
  • 2
  • 3
  • 4
< >
All Rights Reserved © Asia-Pacific Academy of Ophthalmology  
Title×
Confirm
Cancel